Azenta, Inc. (AZTA) Q2 2026 Earnings Call Transcript – Image for illustrative purposes only (Image credits: Pexels)
Burlington, Massachusetts — Investors in Azenta Inc. now face a more cautious outlook after the life sciences company’s second-quarter fiscal 2026 results revealed ongoing demand challenges, particularly in North America. The firm posted revenue of $145 million for the period ended March 31, 2026, marking a 1 percent year-over-year increase on a reported basis but a 3 percent decline organically. This performance, coupled with a significant non-cash goodwill impairment, led executives to trim full-year expectations during the May 6 earnings call.[1][2]
Financial Results Reflect Mixed Segment Dynamics
Azenta’s adjusted EBITDA came in at $8 million, yielding a margin of 5.4 percent, down 320 basis points from the prior year. The decline stemmed largely from reduced volumes and challenges absorbing fixed costs. Gross margin stood at 44.3 percent, a 110 basis point drop, influenced by lower activity levels.
A major drag on GAAP results was a $149 million non-cash goodwill impairment charge, with $112.4 million allocated to the Multiomics segment and $36.6 million to Sample Management Solutions. This contributed to a GAAP operating loss of $165.8 million and diluted EPS loss of $3.41 from continuing operations. On a non-GAAP basis, the company recorded a $0.04 per share loss, compared to a $0.01 profit a year earlier.[3]
| Key Q2 FY2026 Metrics | Q2 FY2026 | Q2 FY2025 | Change |
|---|---|---|---|
| Revenue (Continuing Ops) | $145M | $143.7M | +1% reported / -3% organic |
| Adjusted EBITDA Margin | 5.4% | 8.6% | -320 bps |
| Non-GAAP EPS | $(0.04) | $0.01 | N/M |
| Free Cash Flow | $5M | N/A | Improved via working capital |
Divergent Trends Across Core Segments
Sample Management Solutions generated $81 million in revenue, up 2 percent reported but down 3 percent organically. Growth in biorepository solutions and consumables offset weakness in capital-intensive automated stores and cryogenic systems. The segment’s gross margin improved slightly to 47.4 percent.
Multiomics revenue held flat at $64 million reported, with a 2 percent organic decline. Gains in next-generation sequencing and gene synthesis were tempered by softness in Sanger sequencing. Gross margin fell to 40.2 percent amid volume pressures and regional mix shifts. Executives pointed to North American funding delays and competitive pressures as key factors.[1]
Revised Guidance Signals Protracted Recovery
Azenta lowered its fiscal 2026 organic revenue outlook to a decline of 2 percent to growth of 1 percent, from prior expectations of 3 to 5 percent growth. Reported revenue guidance now stands at $603 million to $621 million. Adjusted EBITDA margin is projected to decline 125 basis points to flat year-over-year, versus earlier hopes for 300 basis points of expansion.
Segment forecasts adjusted accordingly: Sample Management Solutions to low-single-digit organic growth, down from mid-single digits; Multiomics to a mid-single-digit decline, from low-single-digit growth. Free cash flow improvement was tempered to 10 to 15 percent year-over-year. Management anticipates sequential margin gains in the second half, with low-double-digit margins in Q3 and stronger in Q4.[3]
- Q3 organic revenue: Low-single-digit growth
- Q4 organic revenue: Low-single-digit decline (tough comps)
- Interest income: $16M–18M
- Tax rate: 27%–29%
Strategic Focus on Transformation Amid Uncertainty
During the call, CEO John Marotta acknowledged the shortfall candidly. “Overall, Q2 organic revenue was down 3% and adjusted EBITDA margin of 5.4% did not meet our expectations,” he stated. He emphasized a priority transformation in Multiomics under new leadership, including lab optimizations and commercial enhancements via the Azenta Business System.
The company extended its long-range plan to 2029 from 2028, maintaining the same targets amid a $6 billion serviceable addressable market in biorepositories, gene synthesis, and automation. CFO Lawrence Lin highlighted a strong balance sheet with $565 million in cash and no debt. Updates on the delayed B Medical Systems divestiture and U.K. Biocentre integration were also shared, with ongoing quality remediations in automated stores nearing completion.[2]
For Azenta’s stakeholders — from biotech partners reliant on its tools to shareholders eyeing returns — the path forward hinges on execution in a measured demand environment. While near-term pressures persist, recurring revenue streams and productivity gains offer a foundation for eventual rebound, though patience will be required as the company navigates these adjustments.